FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-04-24

Price

$14.49

+0.21%

Score10.5Priority

Signals4/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 9

Volume1.5xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is trading at a 52-week high because it just received final regulatory clearance from France for its $4.8 billion acquisition by BioMarin Pharmaceutical. This decisive M&A catalyst completely explains the PERFECT_STACK and QUIET_STORM technical signals, as institutional arbitrageurs pin the stock tightly to its buyout price. Furthermore, the highly supportive RISK_ON macro regime and ultra-low 0.80% High Yield credit spreads provide absolute market confidence that financing and systemic risks are non-existent. The market is pricing in complete certainty for the deal's expected close on April 27, 2026.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONWEAK FINISH

Key Takeaways

Actionable Thesis: FOLD is a finalized M&A arbitrage play pinned at $14.49, with the $4.8B BioMarin acquisition fully cleared to close on April 27, 2026.
Key Risk: Tail-risk of an unforeseen, 11th-hour legal injunction or contract breach by BioMarin before the closing date.
What to Watch: The mechanical execution of the merger close on April 27, 2026, and the maintenance of the $14.41 support level which acts as the arbitrage floor.

← Back to 2026-04-24 View Full FOLD History →Yahoo Finance &nearr;